262 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
8:11am
that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases … , the expected timing of topline data from the HELIOS-B Phase 3 clinical study, and the planned achievement of its “Alnylam P5x25” strategy, should
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare … ” strategy, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward
8-K
EX-99.1
esvedtaj7vmhsoqof
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
EX-99.1
f7o2d66g8sl
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
xmyk80q3nhd
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
x6vfnqzc
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
oolub96r32a
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
11bnwi9r
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
wtt 0uboq4ujpfeqfnz3
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
e6k iatcru82k
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.2
loowtb
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm